LENZ Therapeutics Inc LENZ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LENZ is a good fit for your portfolio.
News
-
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
-
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
-
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
-
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
-
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
Trading Information
- Previous Close Price
- $16.18
- Day Range
- $15.00–16.22
- 52-Week Range
- $14.07–29.82
- Bid/Ask
- $15.06 / $18.17
- Market Cap
- $393.22 Mil
- Volume/Avg
- 115,759 / 104,955
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.lenz-tx.com
Valuation
|
Metric
|
LENZ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LENZ
|
|---|---|
Quick Ratio | 5.23 |
Current Ratio | 5.34 |
Interest Coverage | — |
Quick Ratio
LENZ
Profitability
|
Metric
|
LENZ
|
|---|---|
Return on Assets (Normalized) | −78.55% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
LENZ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pljxqvcsl | Vvcz | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sfhpbqxsv | Fynmpm | $105.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kcybclb | Fyrjbtt | $105.3 Bil | |
MRNA
| Moderna Inc | Ftffxbpk | Ysh | $46.7 Bil | |
ARGX
| argenx SE ADR | Rhkgkvtk | Lqfh | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Scsjykwy | Jpvd | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ghqczwxb | Ryscy | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Npvhtkql | Yxfsg | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ddbhdycp | Xgvmmj | $12.6 Bil | |
INCY
| Incyte Corp | Rcgqcpt | Tgkksgz | $12.0 Bil |